Zacks Rank on Eli Lilly and Company (LLY) based on Estimated Earnings

Barsaba Taglieri
Marzo 18, 2017

The company had a trading volume of 1,330,639 shares. A lower P/B ratio could mean that the stock is undervalued. Northern Trust Corp now owns 11,550,654 shares of the company's stock worth $927,056,000 after buying an additional 120,175 shares during the last quarter. The low EPS estimate is $0.87, while the high EPS estimate is $1.24.

When we look at the Analyst Recommendations of the stock, the company has 2.5 rating given by Analysts where 1 stands for Strong Buy and 5 stands for Strong Sell.

Eli Lilly and (NYSE:LLY) last released its earnings results on Tuesday, January 31st. Strategic Financial Group LLC raised its position in shares of Eli Lilly and by 0.5% in the third quarter.

Wynn Resorts, Limited (NASDAQ:WYNN), stock is trading $108.30 above the 52-week high and has displayed a high EPS growth of -13.40% in last 5 years. Eli Lilly and Co has a 1-year low of $64.18 and a 1-year high of $84.77.

Pharma major Eli Lilly and Company on Thursday announced launch Humalog 200U/mL KwikPen - used in the treatment of diabetes - in the Indian market.

The analysts offering 12 month price targets for Eli Lilly and Company have a median target of $88, with a high estimate of $103 and a low estimate of $70. The company has a market cap of $92,836 million and there are 1,103,352,450 shares in outstanding. The stock appeared 1.31% below its 52-week highs and is up 2.96% for the last five trades.

While looking at the Stock's Performance, Eli Lilly and Company now shows a Weekly Performance of 2.96%, where Monthly Performance is 10.43%, Quarterly performance is 27.88%, 6 Months performance is 10.89% and yearly performance percentage is 23.76%.

"Freestone Capital Holdings LLC Purchases 1,272 Shares of Eli Lilly and Co (LLY)" was first published by Community Financial News and is owned by of Community Financial News. The firm has a 50 day moving average of $80.63 and a 200 day moving average of $77.04. During the same quarter in the previous year, the firm earned $0.78 earnings per share. Analysts expect that Eli Lilly and Co will post $4.10 earnings per share for the current fiscal year. The company's revenue for the quarter was up 7.2% on a year-over-year basis. Company price to earnings (P/E) ratio, which measures the relationship between the earnings of a company and its stock price, is calculated as 33.31. Integrated Wealth Management boosted its stake in Eli Lilly and by 3.7% in the third quarter. Hedge funds and other institutional investors own 75.15% of the company's stock. The count of Hold ratings in that period was 1. Jefferies Group LLC boosted their target price on Eli Lilly and from $90.00 to $93.00 and gave the company a "buy" rating in a research note on Friday, January 20th. The reported earnings per share topped the analyst's consensus by $-0.03 with the percentage difference between estimated and actual earnings arriving at -3.10%.

In other Eli Lilly and news, Director R David Hoover bought 500 shares of the stock in a transaction that occurred on Friday, December 16th. The company's shares were closed at $36.28.

In the transaction dated February 02, 2017, the great number of shares disposed came courtesy the Chief Accounting Officer; Zakrowski Donald A disposed a total of 2,000 shares at an average price of $77.52, amounting to approximately $155,040. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Following the sale, the insider now owns 8,169 shares in the company, valued at approximately $671,736.87. With the volume soaring to 2,248,486 shares, the last trade was called at $84.14. Following the completion of the sale, the senior vice president now owns 45,583 shares in the company, valued at approximately $3,539,975.78.

"Humalog 200U/mL KwikPen provides physicians a new prescription option for their patients", Eli Lilly and Company (India) MD Edgard Olaizola said.

Eli Lilly and Company discovers, develops, manufactures, and sells products in one significant business segment -pharmaceutical products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Altre relazioni OverNewsmagazine

Discuti questo articolo